Recent Patents on Influenza Vaccines

被引：0
作者：
Department of Chemical Engineering, National Tsing Hua University, Hsinchu, Taiwan [1 ]
机构：
[1] Department of Chemical Engineering, National Tsing Hua University, Hsinchu
来源：
Recent Pat. Biotechnol. | 2007年 / 3卷 / 234-242期
关键词：
adenovirus; adjuvant; attenuated virus; DNA vaccine; inactivated virus vaccine; Influenza vaccine; influenza virus; peptide vaccine; reverse genetics; subunit vaccine; virus-like particles;
D O I：
10.2174/187220807782330192
中图分类号：
学科分类号：
摘要：
Influenza virus is the pathogen responsible for the epidemic influenza and current vaccines include inactivated and live attenuated viruses which are produced in chicken eggs. However, these vaccines posses various drawbacks of their own and the protection rate ranges from 30~80% depending on match between strains included in the vaccine and circulating strains, leaving significant room for improvement. This review provides background information regarding the influenza vaccines and extends the discussion with an emphasis on the new patents published or granted over the last five years. These patents primarily aim at ameliorating existing bottlenecks in vaccine development and are associated with vaccine compositions that provide strong vaccine efficacies and broader cross-reactivity, and various vaccine platforms such as DNA vaccines, recombinant subunit, peptide and viral vector vaccines. © 2007 Bentham Science Publishers Ltd.
引用
收藏
页码：234 / 242
页数：8
相关论文
共 87 条
[1]  
Brown EG., Influenza virus genetics, Biomed Pharmacother, 54, pp. 196-209, (2000)
[2]  
Wright PF, Webster RG., Virology, pp. 1533-1579, (2001)
[3]  
Krug RM, Soeiro R., Studies on the intranuclear localization of influenza virus-specific proteins, Virology, 64, pp. 378-387, (1975)
[4]  
Qiu Y, Krug RM., The influenza virus NS1 protein is a poly(A)-binding protein that inhibits nuclear export of mRNAs containing poly(A), J Virol, 68, pp. 2425-2432, (1994)
[5]  
Maassab HF, Herlocher ML, Bryant ML., Vaccines, pp. 909-927, (1999)
[6]  
Kilbourne ED., Future influenza vaccines and the use of genetic recombinants, Bull World Health Organ, 41, pp. 643-645, (1969)
[7]  
Kilbourne ED, Arden NH., Vaccines, pp. 531-551, (1999)
[8]  
Maassab HF., Adaptation and growth characteristics of influenza virus at 25<sup>o</sup>C, Nature, 213, pp. 612-614, (1967)
[9]  
Maassab HF, DeBorde DC., Development and characterization of cold-adapted viruses for use as live virus vaccines, Vaccine, 3, pp. 355-369, (1985)
[10]  
Belshe RB, Mendelman PM, Treanor J, Et al., The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children, N Engl J Med, 338, pp. 1405-1412, (1998)
123456789